KLP Kapitalforvaltning AS Buys New Shares in Humana Inc. (NYSE:HUM)

KLP Kapitalforvaltning AS purchased a new position in Humana Inc. (NYSE:HUM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,770 shares of the insurance provider’s stock, valued at approximately $10,629,000.

Several other institutional investors have also recently made changes to their positions in the stock. FPC Investment Advisory Inc. purchased a new stake in Humana in the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana in the fourth quarter worth approximately $30,000. LFA Lugano Financial Advisors SA increased its stake in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana during the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. lifted its stake in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.37% of the company’s stock.

Humana Trading Up 2.1 %

HUM stock opened at $271.65 on Tuesday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The stock has a market capitalization of $32.79 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm’s fifty day simple moving average is $271.01 and its two-hundred day simple moving average is $275.60.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Morgan Stanley decreased their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Piper Sandler upped their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. reduced their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Eighteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.